Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma

Tetsuya Isaka, MD, Tomoyuki Yokose, PhD, Hiroyuki Ito, PhD, Masashi Nagata, MD, Hideyuki Furumoto, MD, Teppet Nishii, MD, Kayoko Katayama, PhD, Kouzo Yamada, PhD, Haruhiko Nakayama, PhD, and Munetaka Masuda, PhD

Abstract: Advanced lung cancers with epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19s) and EGFR exon 21 L858R point mutations (Ex21s) exhibit different clinical behavior. However, these differences are unclear in resectable primary lung tumors. The clinicopathological features of 88 (20.9%) Ex19, 124 (29.4%) Ex21, and 198 (46.9%) EGFR wild-type (Wt) clinical stage I primary adenocarcinomas resected between January 1, 2012 and October 31, 2014 were compared by using Chi-square tests, residual error analysis, analysis of variance, and Tukey tests. Ex21 lesions occurred more frequently in women and never-smokers and had a higher tumor disappearance rate (TDR: 59.6% vs 43.9%; P < 0.001) and lower maximum standardized uptake value (maxSUV: 2.0 vs 3.5; P < 0.01) than Wt lesions; Ex19 lesions had intermediate values (52.8% and 2.6). There was a low frequency of vascular invasion in Ex21 lesions (12.1%; P < 0.05) and a high frequency in Wt lesions (22.7%; P < 0.05). Most Ex19 lesions were intermediate-grade adenocarcinoma (lepidic, acinar, and papillary predominant: 73.9%; P < 0.05). Wt and Ex21 lesions were predominately high-grade (micro-papillary or solid predominant, mucinous variant) and low-grade (adenocarcinoma in situ and minimally invasive adenocarcinoma) adenocarcinoma, respectively. Wt lesions had smaller lepidic components (42.1% vs 56.3%; P < 0.001) and larger papillary and solid components (papillary: 15.5% vs 9.0%; P < 0.05; solid: 13.2% vs 3.2%; P < 0.001) than Ex21 lesions. Most Ex19 lesions had intermediate component rates. Most Ex21 lesions were low-grade adenocarcinoma with lepidic growth patterns. Wt high-grade adenocarcinomas included solid and papillary components with vascular invasion. Ex19 lesions were intermediate grade between Ex21 and Wt.

(Medicine 94(42):c1784)

INTRODUCTION

Epidermal growth factor receptor (EGFR) gene mutations occur in 10% to 50% of stage IV nonsmall cell lung cancer. EGFR mutations are frequently observed in adenocarcinomas as well as in Asian women who are nonsmokers.1–3 The EGFR status is the most important determining factor for tyrosine kinase inhibitor (TKI) treatment.4,6 EGFR mutations are found in 30% to 50% of lung adenocarcinomas, with the most common mutations being the EGFR exon 19 deletion (Ex19) and EGFR exon 21 L858R point mutation (Ex21). These 2 mutations account for 85% to 90% of EGFR mutations.4–8 TKIs, which bind to the tyrosine kinase domain of EGFR, have demonstrated clinical efficacy for the treatment of advanced lung adenocarcinoma.9,10 Lesions with Ex19 and Ex21 mutations are thought to exhibit different clinical behavior, and some previous reports demonstrated that Ex19 lesions responded better to EGFR-TKIs and platinum-based chemotherapy than Ex21 lesions in a population with unresectable lung cancer.10–14

Previous studies have reported differences in clinicopathological features between EGFR mutant (Mt) and EGFR wild-type (Wt) resectable lung adenocarcinomas, including differences in histopathological features,15–17 patient prognosis,15,18,19 and radiological imaging findings.20,21 Most previous studies have indicated that Mt tumors are associated with better prognosis than Wt tumors.15,18,19 Mt tumors have been pathologically characterized in past reports as having a non-mucinous lepidic growth pattern.15,16,21–24 However, other studies reported that Mt tumors are highly correlated with a papillary growth pattern,15,17 an acinar predominant (AP) pattern,25 or a micropapillary growth pattern.23,26–29 As the differences between Ex19, Ex21, and Wt tumors remain unclear, we examined the correlations between the EGFR mutation status and clinicopathological features in resected clinical stage I lung adenocarcinoma based on radiological images and histological
subtypes according to the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011IASLC/ATS/ERS classification).

METHODS

Patients

There were 429 patients who were clinical stage I disease without receiving preoperative treatment or without the evidence of the synchronous multiple lung cancer, between January 1, 2012 and October 31, 2014. Of the 429 patients, the EGFR mutation status was analyzed in 422 patients (98.4%). Of the 422 patients, total 410 patients were enrolled in this study: 88 patients (20.9%) with Ex19 lesions, 124 patients (29.4%) with Ex21 lesions, and 198 patients (46.9%) with WT lesions. We performed statistical comparisons among these groups. The 12 patients with the other mutation statuses were excluded in this study: 8 patients (1.9%) with exon 18 mutations (G719X), 3 patients (0.7%) with exon 21 mutations (L861Q), and 1 patient (0.2%) with a double mutation.

Radiological Examinations

Chest computed tomography (CT) images were obtained using an X-Vigor/Real CT scanner or an Aquilion CT scanner (Toshiba Medical Systems, Tochigi, Japan). CT tumor size was determined from high-resolution CT scans with a 1-mm section thickness. The maximum axial tumor size in a pulmonary window level setting (TSPW: level, −600 HU; width, 1600 HU) and tumor size in a mediastinal window level setting (TSMW: level, 40 HU; width, 400 HU) were measured. The tumor disappearance rate (TDR) was calculated based on the following formula: TDR = 1 – (TSMW/TSPW) × 100 (%).

Pathological Examinations

More than 1 pathologist, including TY, examined all resected specimens and measured pathological tumor size at the place where the tumor appeared to be maximal in size. Sections were stained with Elastica-van Gieson staining to evaluate vascular invasion and pleural invasion, as well as lymphatic and vascular invasion. Lung adenocarcinomas were classified based on the predominant subtype as defined by the 2011IASLC/ATS/ERS classification and subtype semiquantitatively by assessing each component in 5% increments. Based on the predominance of the components, lung adenocarcinoma specimens were categorized as adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma (InvAd)-lepidic predominant (LP), InvAd-AP, InvAd-AP-papillary predominant (PP), InvAd-micropapillary predominant (MP), InvAd-solid predominant (SP), and InvAd-mucinous variant (MV). Each pulmonary adenocarcinoma subtype was further categorized as low-grade adenocarcinoma (AIS, MIA), intermediate-grade adenocarcinoma (InvAd-LP, InvAd-AP, InvAd-PP), or high-grade adenocarcinoma (InvAd-Sp, InvAd-MP, InvAd-MV) based on prognosis, as previously reported by Yoshizawa et al.

EGFR Mutation Analysis and Statistical Analysis

DNA extraction was performed using the QIAamp DNA FFPE kit (Qiagen K.K., Tokyo, Japan) in accordance with the manufacturer’s instructions. Eight sections (thickness, 5–10 μm) were made from a formalin-fixed paraffin-embedded block of tumor tissue, and the section with the largest amount of tumor cells was identified by hematoxylin and eosin staining. The sections were deparaffinized with 1 mL xylene, and the xylene was then removed with 1 mL ethanol (96%–100%). The remaining pellet was resuspended with 180 μL ATL buffer, and incubated with 50 μL proteinase at 56 °C for 1 hour or until the sample was completely lysed. After sequential incubation of the sample at 90 °C for 1 hour, 200 μL AL buffer and ethanol (96%–100%) were added. The lysate was transferred to a QIAamp MinElute Column and centrifuged, and the sample was completely lysed. After sequential incubation of the sample at 90 °C for 1 hour, 200 μL AL buffer and ethanol (96%–100%) were added. The lysate was transferred to a QIAamp MinElute Column and centrifuged, and the sample was completely lysed. After sequential incubation of the sample at 90 °C for 1 hour, 200 μL AL buffer and ethanol (96%–100%) were added. The lysate was transferred to a QIAamp MinElute Column and centrifuged, and the sample was completely lysed. After sequential incubation of the sample at 90 °C for 1 hour, 200 μL AL buffer and ethanol (96%–100%) were added. The lysate was transferred to a QIAamp MinElute Column and centrifuged, and the sample was completely lysed.

A fragment method was used to detect Ex19/insertion. Mt genes were amplified by polymerase chain reaction on a Thermal Cycler Dice TP600 (Takara Bio Inc., Shiga, Japan), following which Ex19/insertion was detected by an ABI3130x1 Genetic Analyzer (Life Technologies Japan, Tokyo, Japan). To detect exon 18 mutations (G719X), exon 20 mutations (T790M), and exon 21 mutations (L858R and L861Q), the Cycleave method was used based on the basic principle of real-time polymerase chain reaction. Mt genes were amplified using a Thermal Cycler Dice Real-Time System, TP800 (Takara Bio Inc., Shiga, Japan); the specific sequence of the amplified gene fragment was detected with a high sensitivity after hybridization of chimeric probes for each Mt with the complementary specific sequence. All the patients provided informed consent for all the parts of this study, before the operation. This study was approved by the Institutional Review Board at Kanagawa Cancer Center, and followed the tenets of the Declaration of Helsinki.

We compared continuous variables among the 3 groups using analysis of variance and post hoc comparisons test (Tukey test). Categorical variables were compared among the 3 groups using Chi-square tests. To determine which groups were significantly different after Chi-square analysis, we consecutively performed a residual error analysis. All P-values less than 0.05 were considered statistically significant.

RESULTS

Clinical background information for patients with lesions with the 3 EGFR statuses is compared in Table 1. Ex21 tumors were common in women and nonsmokers (P < 0.01 and <0.001, respectively), while Wt tumors were common in men and smokers (P < 0.001 for both). The TDR was lower in Wt than in Ex21 tumors (43.9% vs 59.6%; P < 0.001), and the maxSUV was higher in Wt than in Ex21 tumors (3.2 vs 2.0; P < 0.01). There were no significant differences in age, location of the lesion (right or left side), or CT tumor size among the 3 groups. Ex19 tumors had values that were intermediate between Ex21 and Wt with regard to the frequency of male patients, frequency of smokers, TDR, and maxSUV.
Pathological background information is compared in Table 2. There were no significant differences in pathological tumor diameter, pathological stage, lymphatic invasion, or pleural invasion among the 3 groups. There was a low frequency of vascular invasion in Ex21 lesions (12.1%; $P < 0.05$) and a high frequency in Wt lesions (22.7%; $P < 0.05$). There was a higher frequency of lymph node metastasis in Ex19 lesions (13.6%) than in Wt and Ex21 lesions (9.1% and 5.6%, respectively), although this difference was not significant ($P = 0.119$).

Figure 1 shows the percentage of tumors with each of the 3 EGFR statuses for each adenocarcinoma subtype based on the 2011 IASLC/ATS/ERS classification. Mt tumors more commonly comprised the AIS, MIA, InvAd-LP, InvAd-AP, and InvAd-MP subtypes than the Wt tumors; Ex21 mutations occurred at approximately twice the incidence rate of Ex19 mutations in AIS and MIA subtype tumors.

Figure 2 shows the frequency of each adenocarcinoma subtype in patients with the 3 EGFR statuses. The frequency of the AIS and MIA subtypes was higher in the Ex21 mutation group (16.9% and 11.3%, respectively) than in the other EGFR status groups. The frequency of InvAd-LP and InvAd-AP was higher in both the Ex21 mutation group (32.3% and 25.8%, respectively) and Ex19 mutation group (33.0% and 28.4%, respectively) than in the Wt group (24.7% and 18.7%, respectively). The frequency of InvAd-PP, InvAd-SP, and InvAd-MV was higher in the Wt group (14.7%, 12.6%, and 6.6%, respectively) than in the Ex19 and Ex21 mutation groups.

The frequency of intermediate-grade adenocarcinoma was significantly high in the Ex19 mutation group (73.9%; $P < 0.05$) and low in the Wt group (58.1%; $P < 0.01$) (Figure 3). The frequency of high-grade adenocarcinoma was significantly high in the Wt group (20.2%; $P < 0.01$) and low in the Ex21 (4.0%; $P < 0.01$) and Ex19 groups (5.7%; $P < 0.05$). Low-grade adenocarcinoma tended to occur at a higher frequency in the Ex21 group (28.3%) compared to the Ex19 (20.4%) and Wt groups (21.7%).

### Table 1. Comparison of Clinical Backgrounds Among Patients With Tumors With the 3 EGFR Statuses

| Total n = 410 | Ex19 (n = 88) | Ex21 (n = 124) | Wt (n = 198) | P Values* |
|---------------|--------------|---------------|-------------|-----------|
| Age           | 67.1 (39.8)  | 68.5 (37.1)   | 67.6 (58.1) | 0.619     |
| Male, %       | 35           | 46            | 115         | 0.001     |
| Smoking history, % | 39 (44.3)   | 39 (31.5)     | 121 (61.1)  | 0.001     |
| Right side, % | 47 (53.4)    | 74 (59.7)     | 121 (61.1)  | 0.466     |
| CT tumor size, mm | 23.0        | 22.5          | 23.0        | 0.915     |
| TDR, %        | 52.8         | 59.6          | 43.9        | 0.001     |
| PET (maxSUV)  | 2.6          | 2.0           | 3.5         | 0.001     |

CT = computed tomography, EGFR = epidermal growth factor receptor, Ex19 = exon 19 deletion, Ex21 = exon 21 L858R point mutation, maxSUV = maximum standardized uptake value, PET = positron emission tomography, TDR = tumor disappearance rate, Wt = wild-type.

*P values were determined by Chi-square tests or analysis of variance.

### Table 2. Comparison of Pathological Backgrounds Among Patients With Tumors With the 3 EGFR Statuses

| Total n = 410 | Ex19 (n = 88) | Ex21 (n = 124) | Wt (n = 198) | P Values* |
|---------------|--------------|---------------|-------------|-----------|
| Pathological tumor size, mm | 23.6 (69.3)   | 24.8 (14.8)   | 32.1        | 0.219     |
| Pathological stage, % | 90 (72.6)     | 23 (18.5)     | 125 (63.1)  | 0.204     |
| IA            | 13 (14.8)    | 7 (8.0)       | 1 (0.0)     | 1 (1.1)   | 0.976     |
| IB            | 6 (6.8)      | 1 (0.8)       | 8 (6.5)     | 1 (0.5)   | 0.037     |
| IIA           | 1 (1.1)      | 0 (0.0)       | 0 (0.0)     | 22 (11.1) | 0.003    |
| IIIB          | 13 (12.1)    | 15 (12.1)     | 45 (22.7)   | 0.037     |
| Vascular invasion, % | 14 (15.9)    | 14 (10.9)     | 35 (17.7)   | 0.099     |
| Pleural invasion, % | 12 (13.6)    | 7 (5.6)       | 18 (9.1)    | 0.119     |

EGFR = epidermal growth factor receptor, Ex19 = exon 19 deletion, Ex21 = exon 21 L858R point mutation, Wt = wild-type.

*P values were determined by Chi-square tests or analysis of variance.
The lepidic component rate was significantly higher in Ex21 tumors (56.3%) than in Wt tumors (42.1%; \( P < 0.001 \)), while the papillary component rate was higher in Wt tumors (15.5%) than in Ex21 tumors (9.0%; \( P < 0.05 \)) (Figure 4). The solid component rate was higher in Wt tumors (13.2%) than in Ex21 (3.2%; \( P < 0.001 \)) and Ex19 tumors (4.4%; \( P < 0.01 \)). The acinar component rate was the highest in the Ex19 group (29.6%; \( P = 0.344 \)). The other adenocarcinoma component rates in the Ex19 group were intermediate values that fell between the rates for the Ex21 and Wt groups.

### DISCUSSION

EGFR is a transmembrane receptor that has intrinsic tyrosine kinase activity and has several specific ligands, such as the epidermal growth factor that binds to EGFR and initiates multiple signaling pathways essential for different cell functions.\(^2\),\(^5\) Mutations of the EGFR genes may result in persistent activation of the tyrosine kinase related to EGFR in tumor cells, and may thus promote tumor proliferation, cell survival, and other cancer-related properties.\(^3\),\(^10\),\(^11\) TKI binds to the tyrosine kinase domain to inhibit the protein kinase activity of EGFR, and the EGFR mutation may be the most important predictor of responsiveness to TKI.\(^4\),\(^10\),\(^12\),\(^13\),\(^14\) In recent years, determination of EGFR gene status has played an extremely important role in TKI selection for advanced lung cancer treatment. Exploring the clinicopathological characteristics of lung cancer with EGFR mutations is considered very important for lung cancer treatment. Many studies have reported clinicopathological differences between Wt and Mt tumors, but few studies have examined differences between 2 common EGFR mutations: Ex21 and Ex19. EGFR mutations are frequently found in Asian women who are...
These classifications are based on the 5-year disease-free survival rates of each subcategory of pathological stage I lung adenocarcinoma. Wt tumors were 100% for AIS, 100% for MIA, 93.5% for InvAd-LP, 83.7% for InvAd-AP, 75.0% for InvAd-PP, 44.4% for InvAd-SP, and 62.5% for InvAd-MV. High-grade adenocarcinoma including InvAd-SP, InvAd-MP, and InvAd-MV was an independent prognostic factor (hazard ratio, 3.66; \( P = 0.007 \)).

In this study, the Ex21 group included a higher proportion of low-grade adenocarcinoma, whereas the Ex19 group included a higher proportion of intermediate-grade adenocarcinoma, such as InvAd-LP or InvAd-AP. High-grade adenocarcinoma lesions were more frequently Wt tumors instead of Ex19 or Ex21 tumors (Figures 2, 3).

Several studies reported that Mt tumors were mainly composed of the lepidic component, and it was thought that this was mainly true in Ex21, not Ex19, mutant tumors (Figure 4). The solid component rate was significantly higher in Wt tumors than in Ex19 and Ex21 tumors; this is consistent with previous studies in which adenocarcinoma with a solid histologic subtype was strongly associated with KRAS mutations and was rare in Mt tumors. Unlike previous studies in which the papillary histologic subtype was associated with Mt tumors, we observed that the papillary growth pattern was more frequently found in Wt tumors in this study. Most InvAd-MV tumors were Wt (92.9%), which was consistent with a previous report that InvAd-MV tumors were strongly associated with KRAS mutations.

Yanagawa et al examined EGFR gene mutations in 241 resected lung adenocarcinoma specimens (49.6%) from a group of 486 patients. They compared histological subtypes of adenocarcinoma between 131 Mt tumors (including 80 cases of Ex21 [33.2%] and 48 cases of Ex19 [19.9%]) and 110 Wt tumors (45.6%). They reported that 62% of AIS, 60% of MIA, 77% of lepidic, 49% of acinar, 50% of papillary, 28% of solid, and 43% of micropapillary subtype tumors were Mt lesions, which was similar to our results. However, the frequency of InvAd-LP tumors was lower (it was approximately 20%), and the frequency of InvAd-AP and InvAd-SP tumors was higher (it was approximately 10%), in our study (Figure 1) than in previous reports. These results reflect differences in the distribution of EGFR status; our study included a greater proportion of Wt and Ex19 tumors (46.9% and 20.9%, respectively) and a smaller proportion of Ex21 tumors (29.4%) than the study by Yanagawa et al.

Zhang et al reported that Mt tumor status was associated with AP lung adenocarcinoma, while other studies reported that Mt tumors were associated with MP lung adenocarcinoma. Russel et al reported that 22% of stage III (N2) lung cancer were Mt tumors, and acinar and MP lung adenocarcinoma was associated with Mt. Differences in the histologic subtypes of adenocarcinoma associated with Mt tumors were possibly observed because of differences in the ratios of Ex19 and Ex21 mutations; these differences stemmed from sample size, racial differences, and lung cancer stage. Few studies have compared adenocarcinoma histologic subtypes based on 2011 IASLC/ATS/ERS classification correlated with patient prognosis. Yoshizawa et al described the following categories for tumor grade: AIS and MIA are considered low-grade; InvAd-LP, InvAd-PP, and InvAd-AP are considered intermediate-grade; and InvAd-SP, InvAd-MP, InvAd-MV, and InvAd-colloid predominant are considered high-grade. These classifications are based on the 5-year disease-free survival rates of 100%, 84%, and 71% for low-, intermediate-, and high-grade adenocarcinoma, respectively (\( P < 0.001 \)).

Woo et al reported that the 5-year disease-free survival rates for each subcategory of pathological stage I lung adenocarcinoma were 100% for AIS, 100% for MIA, 93.5% for InvAd-LP, 83.7% for InvAd-AP, 75.0% for InvAd-PP, 44.4% for InvAd-SP, and 62.5% for InvAd-MV. High-grade adenocarcinoma including InvAd-SP, InvAd-MP, and InvAd-MV was an independent prognostic factor (hazard ratio, 3.66; \( P = 0.007 \)).
Vascular invasion occurred most frequently in Wt tumors (22.7%; \( P < 0.05 \)) and least frequently in Ex21 tumors. This was consistent with the conclusion that Wt tumors were high-grade malignancies and Ex21 tumors were low-grade malignancies. However, lymph node metastasis was identified most frequently in Ex19 tumors (Table 2). Further studies are necessary to examine whether tumors with Ex19, which is indicative of malignancy that is an intermediate grade (between Wt and Ex21), present with lymph node metastasis at the highest frequency of the 3 EGFR statuses. Moreover, further biomolecular examination is necessary to evaluate correlations between the 3 EGFR statuses and cancer cell invasiveness.

Previous reports demonstrated that Ex21 and Ex19 exhibited different behavior in advanced lung cancer.\(^1,10,12,13,40\) Rosell et al.\(^13\) reported that Ex19 tumors had a better response rate to TKIs than Ex21 tumors (odds ratio, 3.08; \( P = 0.001 \)). Furthermore, Riely et al.\(^12\) reported that patients with Ex19 tumors had a longer overall survival than patients with Ex21 tumors after erlotinib or gefitinib treatment (34 vs 8 months; \( P = 0.01 \)). Fang et al.\(^14\) reported that progression-free survival was longer in patients with Ex19 versus Ex21 tumors treated with first-line platinum-based chemotherapy (\( P = 0.007 \)). It was questionable whether Ex21 tumors, which are characterized as low-grade adenocarcinoma that is anchored by the lepidic growth pattern, progressed to advanced lung cancer that was resistant to TKIs and chemotherapy. Further evaluation is necessary to examine the factors that conclusively differentiate unresectable advanced lung cancer from resectable lung cancer in patients harboring the same EGFR mutation.

Ex19 mutations varied in type, and they included in-frame deletions and mixed insertion/substitutions; delE746_760 and delL747_P753insS were the 2 most common Ex19 mutations. Response to TKIs varies according to the subtype of Ex19.\(^11\) The fragment analysis used in this study to examine Ex19 was not able to detect the number of deleted nucleotides and the start codon in order to identify the subtype of Ex19 mutation. A future study is needed to evaluate correlations between Ex19 mutation subtype and clinicopathological features.

Among the clinical stage I lung adenocarcinoma specimens, Ex21 tumors were predominately low-grade adenocarcinomas with a lepidic growth pattern. Moreover, Wt tumors were frequently high-grade adenocarcinomas that mainly comprise solid and papillary components with vascular invasion. Ex19 tumors appeared to be intermediate-grade adenocarcinomas with characteristics that were intermediate to Ex21 and Wt tumors. The pathological characteristic of the pulmonary lesion and the malignancy grade may be predicted preoperatively if the EGFR status of the lesion can be confirmed using small samples. The correlation between EGFR mutation status and clinicopathological features identified in this study suggest that the prognosis may differ according to the EGFR status among clinical stage I lung adenocarcinomas, and that further study is necessary.

REFERENCES

1. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. \textit{N Engl J Med.} 2009;361:958–967.

2. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. \textit{Clin Cancer Res.} 2004;10:8195–8203.

3. Gazdar AF, Shigematsu H, Herz J, et al. Mutations and addiction to EGFR: the Achilles ‘heel’ of lung cancers? \textit{Trends Mol Med.} 2004;10:481–486.

4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. \textit{N Engl J Med.} 2004;350: 2129–2139.

5. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. \textit{J Clin Oncol.} 2005;23:2556–2568.

6. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. \textit{Oncoogene.} 2009;28:824–831.

7. Pao W, Miller V, Zakowski M, et al. EGFR receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. \textit{Proc Natl Acad Sci U S A.} 2004;101:13306–13311.

8. Riely GJ, Politi KA, Miller VA, et al. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. \textit{Clin Cancer Res.} 2006;12:7232–7241.

9. Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? \textit{Nat Clin Pract Oncol.} 2005;2:554–561.

10. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. \textit{J Clin Oncol.} 2005;23:2513–2520.

11. Lee VH, Tin VP, Choy TS, et al. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. \textit{J Thorac Oncol.} 2013;8:1148–1155.

12. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. \textit{Clin Cancer Res.} 2006;12:839–844.

13. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. \textit{N Engl J Med.} 2009;361:958–967.

14. Fang S, Wang Z, Guo J, et al. Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. \textit{J Thorac Oncol.} 2013;8:52–61.

15. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. \textit{J Thorac Oncol.} 2013;8:52–61.

16. Yanagawa N, Shiono S, Abiko M, et al. The correlation of the EGFR mutation subtype and clinicopathological features. \textit{Ann Thorac Surg.} 2014;98:453–458.

17. Sun PL, Seol H, Lee HJ, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. \textit{J Thorac Oncol.} 2012;7: 323–330.

18. Nishi T, Yokose T, Miyagi Y, et al. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer. \textit{BMC Cancer.} 2014;14:610.

19. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. \textit{J Natl Cancer Inst.} 2005;97:339–346.
20. Yano M, Sasaki H, Kobayashi Y, et al. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol. 2006;1:413–416.

21. Usuda K, Sagawa M, Motono N, et al. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive? Asian Pac J Cancer Prev. 2014;15:657–662.

22. Sonobe M, Manabe T, Wada H, et al. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer. 2005;93:355–363.

23. Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer. 2009;63:235–240.

24. Villa C, Cagle PT, Johnson M, et al. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med. 2014;138:1353–1357.

25. Zhang Y, Sun Y, Pan Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012;18:1947–1953.

26. Zhang Y, Wang R, Cai D, et al. A comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thorac Oncol. 2014;9:1772–1778.

27. Sun Y, Yu X, Shi X, et al. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol. 2014;12:148.

28. Shim HS, Lee da H, Park EJ, et al. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med. 2011;135:1329–1334.

29. Song Z, Zhu H, Guo Z, et al. Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Med Oncol. 2013;30:645.

30. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–285.

31. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011;24:653–664.

32. Nakamura H, Saji H, Shinmyo T, et al. Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography. Lung Cancer. 2015;87:28–33.

33. de Jong WK, van der Heijden HF, Pruijn J, et al. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study. J Thorac Oncol. 2007;2:1007–1012.

34. Kondo T, Yamada K, Noda K, et al. Radiologic-prognostic correlation in patients with small pulmonary adenocarcinomas. Lung Cancer. 2002;36:49–57.

35. Saito H, Kameda Y, Masui K, et al. Correlations between thin-section CT findings, histopathological and clinical findings of small pulmonary adenocarcinomas. Lung Cancer. 2011;71:137–143.

36. Woo T, Okudela K, Mitsu H, et al. Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathol Int. 2012;62:785–791.

37. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857–865.

38. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn. 2007;9:320–326.

39. Russell PA, Barnett SA, Walkiewicz M, et al. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol. 2013;8:461–468.

40. Kaneda T, Hata A, Tomioka H, et al. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. Lung Cancer. 2014;86:213–218.